Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lifco on acquisition of Rapid Granulator
Mandate

Vinge advises Lifco on acquisition of Rapid Granulator

February 20, 2015

Vinge is advising Lifco AB (publ) in connection with the acquisition of Rapid Granulator AB. Lifco acquires and develops market-leading niched operations within the three business areas dental, demolition & tools and systems solutions. Lifco has approximately 100 companies in 30 countries and in 2013, the group’s net sales amounted to more than SEK 6 billion. Rapid Granulator is a leading global manufacturer of granulators for in-plant recycling of plastic waste and in 2014, Rapid Granulator reported net sales of approximately MSEK 300.

The Vinge team advising Lifco AB (publ) includes partner Erik Gabrielson and counsel Kristian Ford together with inter alia associates Henrik Jonsson, Karolina Tjärnberg and Mattias Sköld. Partner Ingela Malmborg provided environmental law advice.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026